Article History
Accepted: 28 September 2020
First Online: 30 October 2020
Competing interests
: R.E.N. has received research grants from H. Lundbeck and Otsuka Pharmaceuticals for clinical trials, received speaking fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen & Cilag, Lundbeck, Otsuka Pharmaceuticals, Servier and Teva A/S, and has acted as an advisor to AstraZeneca, Eli Lilly, Lundbeck, Medivir, Otsuka Pharmaceuticals and Takeda. J.B. and S.E.J. declare no competing interests.